Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

The Council for Responsible Nutrition requests a 90-day extension period to comment on the status of pyridoxamine as a dietary supplement. "There is very strong evidence" that the ingredient was marketed prior to the enactment of DSHEA, CRN maintains in a Dec. 16 letter to FDA. However, the group began contacting members in November for evidence of sale and "the search for documentary evidence is proving difficult and tedious." CRN has identified two firms "whose former employees believe they marketed pyridoxamine during that era" and who are continuing their search for evidence. FDA sought comment in a Nov. 18 Federal Register that "tentatively" concluded the ingredient was not a supplement ("The Tan Sheet" Nov. 21, 2005, p. 13). Debate began when a July citizen petition by BioStratum requested that sales of supplements containing pyridoxamine cease. The firm filed an investigational new drug application in 1999 for Pyridorin, which contains the ingredient...

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts